Table 2.
Measure | Wheezea | Long-standing cougha | Productive cougha | |||
---|---|---|---|---|---|---|
N | % | N | % | N | % | |
Baseline prevalence | 936/5017 | 18.7 | 1086/5017 | 21.7 | 1000/5017 | 19.9 |
Cumulative incidence proportionb | 341/(5017–936) | 8.4 | 350/(5017–1086) | 8.9 | 417/(5017–1000) | 10.4 |
Annual incidence proportion | 341/(5017–936)/6 | 1.4 | 350/(5017–1086)/6 | 1.5 | 417/(5017–1000)/6 | 1.7 |
Remitted proportionc | 442/936 | 47.2 | 658/1086 | 60.6 | 468/1000 | 46.8 |
Annual remitted proportion | 442/936/6 | 7.9 | 658/1086/6 | 10.1 | 468/1000/6 | 7.8 |
Persistent proportiond | (936–442)/936 | 52.8 | (1086–658)/1086 | 39.4 | (1000−468)/1000 | 53.2 |
aThe figures are affected by item non-response, and absolute percentages are presented
bThe number of incident cases divided by subjects at risk (total sample minus subjects with symptoms at baseline)
cThe number of remitted cases divided by the number of subjects with symptoms at baseline
dThe number of persistent cases (subjects with symptoms at baseline minus number of remitted cases) divided by the number of subjects with symptoms at baseline